Scientific and Clinical Insights into Acellular Tissue Engineered Vessels
Registration
Join leading experts for an in-depth discussion on the science, clinical outcomes and real-world application of Symvess® Acellular Tissue Engineered Vessel (ATEV), a conduit innovation in vascular surgery in the last four decades specifically for the vascular trauma indication.
Featured Speakers
Laura Niklason, MD, PhD, Founder, President, and CEO, Humacyte
Dr. Niklason will provide an overview of Humacyte and a scientific analysis of the Symvess® Acellular Tissue Engineered Vessel (ATEV™) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.1
Todd Rasmussen, MD, Vascular Surgeon
Dr. Rasmussen will review ATEV clinical evidence from completed studies and patient cases, and provide insights into intraoperative ATEV handling techniques.
Interactive Discussion
The program will conclude with a live discussion session to address audience questions hosted by Dr. Niklason and Dr. Rasmussen, giving attendees the opportunity to engage directly with the faculty and explore this innovation in greater depth.
About Symvess® Acellular Tissue Engineered Vessel
The United States FDA approval of the Symvess® Acellular Tissue Engineered Vessel (ATEV) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible represents one of the only conduit innovations in vascular surgery in the last four decades specifically for the vascular trauma indication.1 Symvess is a bioengineered human vessel that is readily available off-the-shelf and is designed to repopulate with the patient’s own cells over time.1
Reference
- Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc.
INDICATION: SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
Warnings and Precautions: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
Adverse Reactions: The most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Click here to obtain a copy of the Symvess
U.S. Prescribing Information and Boxed Warning
and see above for Important Safety Information
Trademarks are owned by Humacyte Global Inc.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000321 3/26
Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.